1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>Canada

Canada Tackles Pricing Review Backlog With New Interim Guidance

 
• By Francesca Bruce

Canada’s Patented Medicine Prices Review Board is consulting on further draft interim guidance on pricing to expedite reviews of medicines authorized since July 2022.

Canadian Money
Canada takes aim at pricing review backlog • Source: Shutterstock

Canada’s Patented Medicine Prices Review Board (PMPRB) is seeking comments on new interim guidance that it hopes will slash the growing backlog of new medicines awaiting a price review. The proposed change would mean that new medicines – those authorized since July 2022 when new pricing regulations came into effect – with a price lower than the average price of the new “PMPRB11” basket of comparator countries would be considered to be already reviewed.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Canada

More from North America

What MAHA Means For US FDA: Prevention Is Not What You Think

 
• By Michael McCaughan

US HHS Advisor Calley Means said new pathways for root-cause treatments are part of the HHS Secretary Robert F. Kennedy Jr.’s vision for the FDA. But what most biopharma companies consider preventative medicines are not what he has in mind, nor does he seem to see those companies as part of the solution.

Makary’s Reorganization Decision A Turning Point For US FDA?

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s disavowal of a proposed reorganization plan may be an important turning point in the Trump Administration. The move does not improve the situation, but may mean the administration stops actively making things worse.

Pink Sheet Podcast: Vaccine Review Political Interference, Missed Deadlines A Harbinger Of US FDA Problems?

 
• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors discuss FDA Commissioner Martin Makary’s decision to have one of his assistants lead negotiations for Novavax’s delayed COVID-19 vaccine review, as well as some recent missed review deadlines, which may be the result of recent FDA cuts.